Lang James Paul 4

What Happened James Paul Lang, a director of Halozyme Therapeutics, received two grant awards on May 5, 2026 as part of the company’s director compensation program: 3,796 restricted stock units (RSUs) and 6,040 stock options. Both grants were recorded at $0.00 (awards/grants), i.e., no cash was paid by the director. These are grant awards (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-05-05; Form 4 filed 2026-05-07 (timely filing).
• Grants: 3,796 RSUs @ $0.00 (award); 6,040 stock options @ $0.00 (derivative award).
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote F1 (RSUs): Each RSU converts to one share and vests in full on the earlier of (i) May 5, 2027 or (ii) the issuer’s next annual meeting; subject to a deferral election under the Directors Deferred Equity Compensation Plan — shares released upon completion of director service.
• Footnote F2 (options): Annual director stock option grant; vests in full on the earlier of (i) May 5, 2027 or (ii) the issuer’s next annual meeting.
• Transaction type codes: A = Award/Grant; the 6,040 entry is a derivative award (stock option), not an exercise (no shares were issued or sold at this time).

Context

• RSUs represent the right to receive one share per unit when vested; because these are grants, they do not reflect a purchase or sale by the director.
• The option grant is a typical annual director award and should not be confused with an exercised option or an immediate sale — no exercise or cashless sale was reported.
• These awards are routine director compensation and include multi-month vesting conditions and possible deferral; they are informational for investors but do not by themselves indicate the director’s market sentiment.